Second-line treatments to treat rheumatoid arthritis are being pushed to the front at greater risk to the patient. ...
* The gears of bureaucracy grind slowly . . . And speaking of arthritis, doctors and patients have been recently warned about one of the slow-acting, anti-rheumatic drugs (SAARDs) used as a second-line treatment